适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Abivax
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Phase I study to evaluate the pharmacokinetics, safety and tolerability of multiple oral doses of obefazimod in participants with renal impairment and matched normal kidney function.Moderately to severely active ulcerative colitisCTIS2024-514561-20-00Abivax48
招募中
1 期
A study to investigate the effects of multiple doses of obefazimod on a combined oral contraceptive (ethinyl estradiol/drospirenone) in healthy female participants of childbearing potential.Healthy female participants of childbearing potential.MedDRA version: 21.1Level: LLTClassification code: 10003268Term: Arthritis rheumatoid Class: 10028395MedDRA version: 20.1Level: PTClassification code: 10021972Term: Inflammatory bowel disease Class: 100000004856CTIS2023-505297-15-00Abivax36
进行中（未招募）
1 期
A study in two groups of healthy male adult participants to assess how much test medicine (SAR441566) is taken up, degraded and removed by the body and to assess the extent to which SAR441566 becomes available to the body when given by mouthCTIS2023-508030-33-00Sanofi-Aventis Recherche & Developpement13
招募中
1 期
An exploratory study to investigate the effect of FE 999302 when given together with follitropin delta during controlled ovarian stimulatioInfertility in women undergoing assisted reproductive technologies (ART)CTIS2023-507630-25-00Ferring Pharmaceuticals A/S600
进行中（未招募）
1 期
APRILIAH (Aprogen Phase III Clinical Trial to Compare Efficacy, Safety, and Immunogenicity of AP063 in Subjects with HER2+ Breast Cancer)CTIS2023-506975-83-00Aprogen Inc.720